Aktis Oncology, Inc. (AKTS) has a consensus analyst rating of Buy, based on 7 analysts covering the stock. Of those, 4 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for AKTS is $31.00, representing a +73.8% upside from the current price of $17.84. Price targets range from a low of $31.00 to a high of $31.00.
